Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Top Execs Stress Importance of Emerging Markets, Compliance in New Year's Addresses
January 6, 2012
- Toray to Take Equity Stake in Mitsui’s Subsidiary
January 6, 2012
- Seikagaku Changes Sales Partner for Supartz in US
January 6, 2012
- Astellas Directed to Suspend Export of Gaster to South Korea Due to Use of Unapproved API
January 6, 2012
- Takara Bio, Mie Univ. to Collaborate in Clinical Trial of Cancer Treatment
January 6, 2012
- Meiji Seika Pharma Submits Application for ME2080 to Treat Dravet’s Syndrome
January 6, 2012
- Tivozanib Significantly Improves PFS Compared to Sorafenib in RCC: Astellas
January 6, 2012
- RaQualia Licenses COX-2 Inhibitor in China
January 5, 2012
- Takeda Voluntarily Recalls Bestcall IM Inj. 0.5 g
January 5, 2012
- Arena Submits Response to FDA CRL for Lorcaserin: Eisai
January 5, 2012
- CanBas’ CBP501 Receives Orphan Drug Designation from US FDA
January 5, 2012
- SymBio Initiates PII Trials for Relapsed, Refractory Multiple Myeloma Treatment SyB L-0501
December 28, 2011
- Nippon Kayaku Starts Clinical Study for Remicade Biosimilar
December 28, 2011
- Sanofi-aventis Completes Patient Enrollment for Int’l ATLAS Study for Lantus
December 28, 2011
- 2 ARB/CCB Combination Products Enter Top 100 Sales Ranking in 1st Half of FY2011
December 28, 2011
- Aricept Overtakes Blopress to Take Top Spot in Domestic Drug Sales
December 28, 2011
- Ain Pharmaciez’s Generic Drug Wholesale Subsidiary Showing Steady Growth
December 28, 2011
- Fuji Pharma, Mochida Apply for Japan’s 1st G-CSF Biosimilar
December 27, 2011
- Nippon Kayaku: Pharm Sales Remains Virtually Unchanged in Jun-Nov
December 27, 2011
- Novartis Receives Add’l Approval for Afinitor as 1st pNET Indication in Japan
December 27, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…